Overseas Headlines – October 4, 2021

United States:

The Real Cost of U.S. Debt Is Nearer the Floor Than the Ceiling

“U.S. politicians are locked in a huge fight over something that more and more people in the financial world view as irrelevant. Brinkmanship in Washington over whether to raise the debt ceiling or risk a default has become a 21st-century staple. But since the last major standoffs a decade or so ago, there’s been a sea change in the way investors, economists and officials think about public borrowing.”

https://www.bloomberg.com/news/articles/2021-10-04/the-real-cost-of-u-s-debt-is-nearer-the-floor-than-the-ceiling?srnd=economics-vp&sref=FmvzgEwg

Europe:

ECB’s Visco Says Price Increases Should Be Only Temporary

“Recent price increases are being driven by commodity inflation and supply-chain snags should prove only temporary, European Central Bank Governing Council member Ignazio Visco said on Saturday. In a speech commemorating economist Marcello De Cecco, Bank of Italy governor Visco said that for now there’s little evidence of higher supply-chain prices being passed through to consumers.”

https://www.bloomberg.com/news/articles/2021-10-02/ecb-s-visco-says-price-increases-should-be-only-temporary?srnd=economics-vp&sref=FmvzgEwg

Asia:

Merck’s Covid Pill Progress Sparks Asian Vaccine Stock Selloff

“Makers of vaccines and other coronavirus treatments dropped in Asia after Merck & Co. said its experimental pill cuts the risk of hospitalization and death from Covid-19 in half.  The declines followed a slump in shares of BioNTech SE and Moderna Inc. in New York on Friday after Merck delivered the news on its drug, which is seen by some as marking a turning point in the global fight against Covid-19.”

https://www.bloomberg.com/news/articles/2021-10-04/merck-s-covid-pill-progress-sparks-asian-vaccine-stock-selloff?srnd=premium-asia&sref=FmvzgEwg

Disclaimer:

Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.

Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.

2021-10-04T08:43:19-05:00